Chemotherapy and immunotherapy of mediastinal tumor, concentrating on non-Hodgkin's lymphoma

K. Ezaki, M. Okamoto, M. Hirano

Research output: Contribution to journalArticlepeer-review


The prognosis of non-Hodgkin's lymphoma (NHL) with mediastinal involvement is known to be poor. We present our current therapeutic approaches for NHL with poor prognosis. One is alternating non-cross-resistant chemotherapy (CAMBO-VIP) and the other is bone marrow transplantation (allogeneic and autologous). Both of these approaches seem to be promising. Although remission lymphocytes can react with autologous tumor cells, there is no significant correlation between these reactions and patient's prognosis. Thus the presence of specific tumor immunity is still to be elucidated. Lately some cytokines, such as interferon and interleukin 2, are reported to be effective for NHL. It is anticipated that more effective therapeutic approach combined with these cytokines can be developed.

Original languageEnglish
Pages (from-to)785-791
Number of pages7
JournalJapanese Journal of Clinical Radiology
Issue number7
Publication statusPublished - 1992

All Science Journal Classification (ASJC) codes

  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'Chemotherapy and immunotherapy of mediastinal tumor, concentrating on non-Hodgkin's lymphoma'. Together they form a unique fingerprint.

Cite this